Social interaction during chemotherapy treatments can positively influence a cancer patient’s health through improving patient outcomes and patient survival rates.
The study, conducted by the National Human Genome Research Institute (NHGRI) from January 1, 2000, to January 1, 2009, involved 4691 cancer patients who were being treated with chemotherapy in a single outpatient ward. The researchers calculated social influence through the total weighted co-presence among patients, meaning the total time a patient spent with other patients being treated with chemotherapy.
“We had information on when patients checked in and out of the chemotherapy ward, a small intimate space where people could see and interact for a long period of time,” said Jeff Lienert, the lead author in NHGRI’s Social Behavioral Research Branch and National Institutes of Health Oxford-Cambridge Scholars Program fellow. “We used ‘time spent getting chemotherapy in a room with others’ as a proxy for social connection.”
The primary outcome was a patient’s 5-year survival rate which is often regarded as the standard in cancer research. This was determined by the percentage of people who live at least 5 years following the completion of chemotherapy treatment.
The study found that when a patient interacted with someone who died fewer than 5 years post-chemotherapy, they had a 72% chance of also dying within the 5-year period after treatment. However, when patients interacted with someone who survived at least 5 years, their chance of dying within 5 years was at 68%. Furthermore, the researchers predicted that isolated patients had a 69.5% chance of death in the 5 years.
“A 2% difference in survival—between being isolated during treatment and being with other patients—might not sound like a lot, but it’s pretty substantial,” Lienert stated. “If you saw 5000 patients in 9 years, that 2% improvement would affect 100 people.”
The researchers suggest that oncologists consider the social influence by attempting to maximize co-presence among patients through scheduling. Also, patients should be encouraged to find social support in the chemotherapy ward in order to reduce stress.
“Positive social support during the exact moments of greatest stress is crucial. If you have a friend with cancer, keeping him or her company during chemotherapy probably will help reduce their stress,” concluded Lienert. “The impact is likely to be as effective, and possibly more effective, than cancer patients interacting with other cancer patients.”
Social Interaction Among Patients During Chemotherapy Affects Treatment Response
Social interaction during chemotherapy treatments can positively influence a cancer patient’s health through improving patient outcomes and patient survival rates.
Social interaction during chemotherapy treatments can positively influence a cancer patient’s health through improving patient outcomes and patient survival rates.
The study, conducted by the National Human Genome Research Institute (NHGRI) from January 1, 2000, to January 1, 2009, involved 4691 cancer patients who were being treated with chemotherapy in a single outpatient ward. The researchers calculated social influence through the total weighted co-presence among patients, meaning the total time a patient spent with other patients being treated with chemotherapy.
“We had information on when patients checked in and out of the chemotherapy ward, a small intimate space where people could see and interact for a long period of time,” said Jeff Lienert, the lead author in NHGRI’s Social Behavioral Research Branch and National Institutes of Health Oxford-Cambridge Scholars Program fellow. “We used ‘time spent getting chemotherapy in a room with others’ as a proxy for social connection.”
The primary outcome was a patient’s 5-year survival rate which is often regarded as the standard in cancer research. This was determined by the percentage of people who live at least 5 years following the completion of chemotherapy treatment.
The study found that when a patient interacted with someone who died fewer than 5 years post-chemotherapy, they had a 72% chance of also dying within the 5-year period after treatment. However, when patients interacted with someone who survived at least 5 years, their chance of dying within 5 years was at 68%. Furthermore, the researchers predicted that isolated patients had a 69.5% chance of death in the 5 years.
“A 2% difference in survival—between being isolated during treatment and being with other patients—might not sound like a lot, but it’s pretty substantial,” Lienert stated. “If you saw 5000 patients in 9 years, that 2% improvement would affect 100 people.”
The researchers suggest that oncologists consider the social influence by attempting to maximize co-presence among patients through scheduling. Also, patients should be encouraged to find social support in the chemotherapy ward in order to reduce stress.
“Positive social support during the exact moments of greatest stress is crucial. If you have a friend with cancer, keeping him or her company during chemotherapy probably will help reduce their stress,” concluded Lienert. “The impact is likely to be as effective, and possibly more effective, than cancer patients interacting with other cancer patients.”
Patients With DMD Receiving Eteplirsen Show Prolonged Survival, Study Finds
April 25th 2024The study provides evidence of survival benefits among patients with Duchenne muscular dystrophy (DMD) receiving eteplirsen compared with the natural history of the condition.
Read More
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
When Uncontrolled Diabetes and a Fungus Meet: Emergency Treatment of Rhino-Orbital-Cerebral Mucormycosis
April 25th 2024JAMA used a case report of rhino-orbital-cerebral mucormycosis in a patient with uncontrolled diabetes to demonstrate correct and incorrect treatment choices.
Read More
Updates on Adagrasib in CRC and the Importance of Genomic Testing With Dr Jun Gong
December 21st 2023Jun Gong, MD, of Cedars-Sinai Medical Center, discusses the latest data on adagrasib in colorectal cancer, the importance of conducting genomic testing, and more.
Listen
Lack of Mutations Associated With Favorable Prognosis in MPN-U
April 25th 2024While the Dynamic International Prognostic Scoring System and bone marrow blasts may predict overall survival, the lack of certain mutations is also associated with a better prognosis for myeloproliferative neoplasm, unclassifiable (MPN-U).
Read More
What We’re Reading: FDA Approves UTI Antibiotic; Ozempic, Wegovy Price Investigation; US Births Fall
April 25th 2024The FDA recently approved an antibiotic for the treatment of urinary tract infections (UTIs) in women; a Senate committee recently launched an investigation into the prices of Novo Nordisk’s diabetes and weight loss drugs; US births fell last year, resuming a national slide after a previous increase during the pandemic.
Read More
Patients With DMD Receiving Eteplirsen Show Prolonged Survival, Study Finds
April 25th 2024The study provides evidence of survival benefits among patients with Duchenne muscular dystrophy (DMD) receiving eteplirsen compared with the natural history of the condition.
Read More
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
When Uncontrolled Diabetes and a Fungus Meet: Emergency Treatment of Rhino-Orbital-Cerebral Mucormycosis
April 25th 2024JAMA used a case report of rhino-orbital-cerebral mucormycosis in a patient with uncontrolled diabetes to demonstrate correct and incorrect treatment choices.
Read More
Updates on Adagrasib in CRC and the Importance of Genomic Testing With Dr Jun Gong
December 21st 2023Jun Gong, MD, of Cedars-Sinai Medical Center, discusses the latest data on adagrasib in colorectal cancer, the importance of conducting genomic testing, and more.
Listen
Lack of Mutations Associated With Favorable Prognosis in MPN-U
April 25th 2024While the Dynamic International Prognostic Scoring System and bone marrow blasts may predict overall survival, the lack of certain mutations is also associated with a better prognosis for myeloproliferative neoplasm, unclassifiable (MPN-U).
Read More
What We’re Reading: FDA Approves UTI Antibiotic; Ozempic, Wegovy Price Investigation; US Births Fall
April 25th 2024The FDA recently approved an antibiotic for the treatment of urinary tract infections (UTIs) in women; a Senate committee recently launched an investigation into the prices of Novo Nordisk’s diabetes and weight loss drugs; US births fell last year, resuming a national slide after a previous increase during the pandemic.
Read More